Mesothelin as a novel biomarker and immunotherapeutic target in human glioblastoma

Glioblastoma multiforme (GBM) presents the most malignant form of glioma, with a 5-year survival rate below 3% despite standard therapy. Novel immune-based therapies in improving treatment outcomes in GBM are therefore warranted. Several molecularly defined targets have been identified mediating ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhenjiang, Rao, Martin, Poiret, Thomas, Nava, Silvia, Meng, Qingda, von Landenberg, Anna, Bartek, Jiri, Xie, Shanshan, Sinclair, Georges, Peredo, Inti, Dodoo, Ernest, Maeurer, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper: Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655191/
https://www.ncbi.nlm.nih.gov/pubmed/29113296
http://dx.doi.org/10.18632/oncotarget.20303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655191/
https://www.ncbi.nlm.nih.gov/pubmed/29113296
http://dx.doi.org/10.18632/oncotarget.20303

Ejemplares similares